chronic fatigu syndrom treatment wlu neurolog disord ailment unknown etiolog immun system disord syndrom treatment chronic fatigu syndrom cf variabl uncertain condit primarili manag cure treatment includ medic medic treatment complementari altern medicin sytemat review ha cf patient suscept placebo predict low placebo respons compar patient diseas cf associ chemic sensit patient respond lower dose medic compar patient medic treatment antidepress antidepress prescrib cf patient purpos treat secondari depress mood swing low dosag tricycl antidepress sometim prescrib improv sleep qualiti reduc pain howev antidepress side increas cf symptom baselin metabol differ patient find antidepress ani help individu patient therefor matter trial error overal studi antidepress cf mix result studi reduct symptom antidepress benefit autonom nervou system stimul drug atomoxetin strattera stimul autonom nervou system appear posit peopl cf symptom amphetamin amphetamin analog help patient exampl methylphenid ritalin ha significantli better placebo reliev fatigu concentr disturb minor cf patient long term modafinil provigil medic design aid maintain wake ha posit individu cf ha properli studi small studi longterm treatment modafinil benefici cf patient hormon variou hormon tri time time includ specif steroid cortisol thyroid hormon studi perform dr jacob teitelbaum dr kent holtorf incorpor lowdos cortisol therapi demonstr posit result review publish endocr rev apr clear compar hydrocortison trial cf patient placebo control trial carri mckenzi al publish jama sep cdc defin patient mani comorbid psychiatr diagnosi triall hydrocortison plu daili month wa moder signific benefit global health scale specif measur fatigu disabl howev wa signific adren suppress natur function patient hydrocortison second studi publish lancet feb clear al randomis crossov trial cdc patient comorbid psychiatr condit lower dose day activ treatment chosen repres dose replac observ reduct approxim ufc previou studi wa clinic signific fall fatigu score activ treatment return level fatigu popul median score compar placebo larg reduct selfrat disabl score fatigu improv furthermor thi dose hydrocortison wa signific adren suppress seriou advers review conclud howev second treatment studi wa short term onli posit wore rapidli switch placebo thu routin thi strategi treatment recommend evalu subsequ studi publish med jun blockman al perform random placebocontrol doubleblind crossov studi patient fulfil cdc criteria chronic fatigu syndrom combin therapi mgd hydrocortison microgday month activ treatment conclud lowdos combin therapi hydrocortison fludrocortison wa patient chronic fatigu syndrom review studi publish journal chronic fatigu syndrom februari kent holtorf review previou hydrocortison trial regard safeti conclud becaus treatment low physiolog dose cortisol ha safe routin dynam acth test doe adequ diagnost sensit reason therapeut trial physiolog dose cortisol major patient cf fm especi symptom consist adren dysfunct low blood pressur baselin cortisol level low lownorm rang immunoglobulin treatment role intraven immuno gammaglobulin ivigg manag cf unclear follow randomis doubl blind placebo control studi examin immunoglobulin short term efficaci follow studi sever year trial posit lloyd al publish med random doubleblind placebocontrol trial determin highdos ivigg fortynin patient abnorm cellmedi immun particip month wa produc remiss immunolog improv adult patient cf australian criteria follow year wilson al respond improv continu improv includ consid respond month peterson al publish med doubleblind placebocontrol trial iv igg thirti patient cf enrol observ ani signific differ group cdc criteria treat gkg placebo everi day month studi signific therapeut benefit detect term symptom amelior improv function statu despit restor level normal rang major advers experi observ iv igg placebo group row ks publish psychiatr result doubl blind random control trial young adolesc diagnos cdc defin cf test efficaci ivigg thi studi placebo month wa followup month signific differ wa demonstr baselin function score month followup function outcom month advers common activ placebo solut predict respons followup studi year year respons wa deteri overal function time young peopl continu improv signific number disabl studi vollmer conna al wa publish med ninetynin adult patient fulfil diagnost criteria cf australian criteria cdc particip thi doubleblind random placebocontrol trial patient receiv intraven infus placebo solut three dose immunoglobulin gkg monthli basi month dose intraven immunoglobulin wa associ specif therapeut benefit advers reaction typic constitut symptom report patient relationship immunoglobulin treatment apart differ criteria select patient subgroup variou trial review comment mix result trial follow peterson al observ ani differ group trial howev note onli subject complet studi result subject type ii error small sampl size volmaconnor al variabl dosag demonstr differt month howev month followup short period wa signific differ month row adolesc studi month wa signific differ immun modul treatment treatment staphylococc vaccin fibromyalgiachron fatigu syndrom patient ha increas serolog respons result thi respons relat improv clinic outcom rct trial conduct improv regular inject continu maintain benefit andersson al publish journal eur pain small studi cf patient compar vaccin staphylococcu toxoid inject steril water clinic global impress signific improv vaccinetr group followup studi patient vaccin treatment wa continu year fifti percent rehabilit success resum halftim fulltim work zachrisson al publish journal eur pain studi hundr consecut refer patient fulfil acr criteria fm cdc criteria cf enrol randomis control trial receiv activ drug placebo treatment includ weekli inject sb staphylococcu toxoid colour steril water follow booster dose total month treatment wa well toler intentiontotreat analysi respond sb group compar placebo group sixteen patient sb group reduc cpr score compar patient placebo group increas cpr symptom withdraw wa note sb group mainten treatment requir prevent relaps titrat drug hormon supplement jacob teitelbaum al publish journal chronic fatigu syndrom result randomis doubl blind placebo control intent treat studi seventytwo fm patient thirtyeight activ thirtyfour placebo sixtynin met cf cdc criteria receiv activ placebo therapi unifi intervent patient treat indic symptom andor lab test subclin thyroid gonad andor adren insuffici disord sleep suspect neural mediat hypotens nmh opportunist infect suspect nutrit defici patient receiv activ placebo treatment unifi intervent patient receiv sleep melatonin valerium rest plu mix individu basi low dose sever sleep medic high dose singl agent adjust patient hour uninterrupt sleep wake day sedat nutrit support multivitamin magnesium malic acid addit treatment individu base test result clinic histori includ ferrou fumar vitamin levothyroxin synthroid desicc thyroid cortisol cortef dhea testosteron enanth delatestryl male natur testosteron femal estrogen replac uteru natur progesteron femal oxytocin fludrocortison florinef increas dietari salt water potassium sertralin zoloft paroxetin paxil fluoxetin prozac nefazodon serzon nystatin plu sever case itraconazol sporanox metronidazol flagyl follow iodoquinol yodoxin doxycyclin time dure studi antidepress serotonin uptak inhibitor ssri amitriptylin cyclobenzaprin ad patient group drop becaus side group drop reason final visit sixteen activ patient better fourteen better wors wors versu three eleven respect placebo group cochranmantelhaenszel trend test signific improv fm impact questionnair fiq score decreas versu analog score improv versu random regress tender point tpi versu baselin adjust linear model longterm followup year activ group continu increas improv time despit patient abl wean treatment analys antidepress littl impact primari comparison activ placebo treatment nadh treatment forsyth al publish ann allergi asthma immunol random doubleblind placebocontrol crossov studi patient cf evalu efficaci reduc form nicotinamid adenin dinucleotid nadh twentysix elig patient fulfil cdc criteria cf complet studi subject randomli assign receiv nadh placebo period follow washout period subject cross altern regimen final period sever advers observ relat studi drug patient respond favor nadh contrast placebo santaella al report health sci result randomis studi compar oral therapi reduc nicotinamid adenin dinucleotid nadh convent modal treatment patient cf total patient fulfil cdc criteria cf randomli assign nadh nutrit supplement psycholog therapi month twelv patient receiv nadh dramat statist signific reduct symptom score trimest author conclud observ nadh convent treatment trimest trial trend improv modal subsequ trimest warrant assess larger patient sampl medic treatment allergi identif treatment case cfslike symptom caus allergi enzym defici food intoler chronic sinus coeliac diseas irrit bowel syndrom allergi test treatment elimin diet prove benefici complementari altern medicin essenti fatti acid treatment number studi carri supplement oil deriv essenti fatti acid gamma linolen acid gla eicosapentaeno acid epa docosahexaeno acid dha studi efamol marin compris primros oil gla togeth fishoil concentr epa dha behan behan report randomis doubl blind placebo control studi patient post viral fatigu syndrom pvf supplement morn week patient activ treatment placebo oliv oil report improv symptom exhaust ach pain muscl weak lack concentr dizzi vertigo depress memori loss patient activ treatment record fewer episod cardiac palpit tachycardia symptom statist signific improv behan horribin enrol sixtythre adult diagnosi pvf randomis doubleblind placebocontrol studi month patient activ treatment supplement vs placebo paraffin oil report improv improv symptom fatigu ach pain muscl weak lack concentr dizzi vertigo depress memori loss symptom statist signific improv test onli supplement group cellular membran phospholipid efa feedstock return normal doubl blind control studi warren al wa report fifti patient fulfil oxford criteria cf neglig pretreat differ redcel membran rbc lipid compar control studi result signific differ treat placebo patient oppos previou studi differ patient subgroup howev question remain sunflow oil placebo ha therapeut own review cf treatment reid al compar onli behanhorrobin warren studi conclud mix result classifi dietari supplement unknown magnesium cox al publish lancet result randomis doubleblind placebocontrol trial magnesium cf associ casecontrol studi patient cf lower red cell magnesium concentr healthi control subject clinic trial patient cf randomli alloc intramuscular magnesium sulphat everi week week patient placebo patient treat magnesium improv energi level better emot pain judg chang nottingham health profil treat patient benefit treatment patient energi score improv contrast patient placebo felt better differ ci placebo patient better energi score red cell magnesium return normal patient magnesium onli patient placebo review reid al determin subsequ studi fail find defici magnesium peopl chronic fatigu syndrom magnesium treatment dietari supplement unknown anoth review werbach nutrit strategi treat chronic fatigu syndrom compar studi conclud wa margin magnesium defici cf comment trial abov find consist report cf patient magnesiumdefici fail benefit inject magnesium time dosag receiv group magnesium defici patient benefit abov trial conclus margin defici onli contribut clinic manifest chronic fatigu syndrom detriment heal process therefor feasibl identifi object test resolut assur repeat test follow initi treatment moreov becaus rariti seriou advers reaction difficulti rule margin defici becaus therapeut benefit nutrit supplement appear pharmacolog ration consid supplement cf patient nutrient carnitin treatment number random control trial find benefit supplement carnitin ester cdc defin cf trial random crossov design compar lcarnitin amantadin cf patient met cdc criteria medicin month washout period onli lcarnitin time daili statist signific clinic improv studi paramet week treatment clinic paramet ani deterior greatest improv place week lcarnitin treatment randomis control trial cdc defin patient compar acetyllcarnitin propionyllcarnitin combin group cf patient dure week treatment consider improv patient acetylcarnitin group propionylcarnitin group combin group acetylcarnitin significantli improv mental fatigu propionylcarnitin improv gener fatigu attent concentr improv group wherea pain complaint decreas ani group week finish treatment worsen fatigu wa experienc group respect acetylcarnitin group group chang plasma carnitin level correl clinic improv randomis control trial elderli patient met cdc criteria cf psychiatr disord placebo carnitin supplement activ group significantli greater improv variou measur placebo group follow paramet muscl pain prolong fatigu exercis sleep disord physic fatigu mental fatigu fatigu sever scale function statu mini mental examin mmse improv complementari altern medicin usag studi report increas util altern treatment peopl cf vs studi design assess altern medicin perceiv benefit pair cf noncf cotwin twin cf cf altern treatment life larg proport twin consid help futur ascertain altern practic manag cf refer rime ka chalder treatment chronic fatigu syndrome occup medicin doi pmid cho hj hotopf wess placebo respons treatment chronic fatigu syndrom systemat review metaanalysis psychosom med doi pmid jason la taylor rr kennedi cl chronic fatigu syndrom fibromyalgia multipl chemic sensit communitybas sampl person chronic fatigu syndromelik symptom psychosom med pmid clauw dj potenti mechan chemic intoler relat condit ann acad sci pmid gruber aj hudson ji pope hg manag treatmentresist depress disord interfac psychiatri medicin fibromyalgia chronic fatigu syndrom migrain irrit bowel syndrom atyp facial pain premenstru dysphor disord psychiatr clin north pmid nation center infecti diseas treatment patient chronic fatigu syndrom htm center diseas control prevent retriev doctor guid chronic fatigu syndrom da capo press isbn thoma ma smith apan investig longterm benefit antidepress medic recoveri patient chronic fatigu syndrom hum psychopharmacol dec schonfeldtlecuona connemann bj wolf rc braun freudenmann rwbupropion augment treatment chronic fatigu syndrom coexist major depress episod pharmacopsychiatri jul goodnick pj sandov brickman klima ngbupropion treatment fluoxetineresist chronic fatigu syndrom psychiatri nov hicki ib wilson aj wright jm bennett bk wakefield lloyd ar random doubleblind placebocontrol trial moclobemid patient chronic fatigu syndrom clin psychiatri sep blockman persoon van houdenhov bobbaer doe methylphenid reduc symptom chronic fatigu syndrom med doi pmid randal dc cafferti fh shneerson jm smith llewelyn mb file se chronic treatment modafinil benefici patient chronic fatigu syndrome psychopharmacol doi pmid teitelbaum bird weiss gould lowdos hydrocortison chronic fatigu syndrome jama author repli doi pmid holtorf diagnos treatment hypothalamicpituitaryadren hpa axi dysfunct patient chronic fatigu syndrom cf fibromyalgia fm journal chronic fatigu syndrom doi clear aj heap malhi gs wess okean miell februari lowdos hydrocortison chronic fatigu syndrom randomis crossov trial lancet doi pmid mckenzi ofallon dale al lowdos hydrocortison treatment chronic fatigu syndrom random control trial jama pmid blockman persoon van houdenhov lejeun bobbaer june combin therapi hydrocortison fludrocortison doe improv symptom chronic fatigu syndrom random placebocontrol doubleblind crossov studi med pmid clear aj april neuroendocrinolog chronic fatigu syndrom endocr rev pmid lloyd hicki wakefield boughton dwyer doubleblind placebocontrol trial intraven immunoglobulin therapi patient chronic fatigu syndrom med pmid holtorf diagnos treatment hypothalamicpituitaryadren hpa axi dysfunct patient chronic fatigu syndrom cf fibromyalgia fm journal chronic fatigu syndrom doi peterson pk shepard macr al control trial intraven immunoglobulin chronic fatigu syndrom med pmid wilson hicki lloyd al longitudin studi outcom chronic fatigu syndrom bmj pmid row ks year followup young peopl cf follow doubl blind randomis control intraven gammaglobulin trial confer clinic scientif basi cf sydney row ks doubleblind random control trial assess efficaci intraven gammaglobulin manag chronic fatigu syndrom adolesc psychiatr pmid patarcamontero roberto chronic fatigu syndrom advanc epidemiolog clinic basic scienc haworth pr isbn vollmerconna hicki hadzipavlov al intraven immunoglobulin ineffect treatment patient chronic fatigu syndrom med pmid andersson bagbi jr dyrehag gottfri staphylococcu toxoid vaccin pain fatigu patient fibromyalgiachron fatigu syndrom eur pain pmid zachrisson colquenavarro gottfri cg regland mllbi februari immun modul staphylococc prepar fibromyalgiachron fatigu syndrom relat antibodi level clinic improv eur clin microbiol infect di doi pmid teitelbaum al journal chronic fatigu syndrom zachrisson regland jahreskog jonsson kron gottfri cg treatment staphylococcu toxoid fibromyalgiachron fatigu syndrom randomis control trial eur pain pmid naranch park yj repkaramirez ms velard clauw baraniuk jn tender sinu doe alway rhinosinus otolaryngolog head neck surgeri offici journal american academi otolaryngologyhead neck surgeri doi pmid baraniuk jn clauw dj gaumond rhiniti symptom chronic fatigu syndrom ann allergi asthma immunol pmid forsyth lm preuss hg macdowel al chiazz birkmay gd bellanti ja februari therapeut oral nadh symptom patient chronic fatigu syndrom ann allergi asthma immunol pmid santaella font disdier om june comparison oral nicotinamid adenin dinucleotid nadh versu convent therapi chronic fatigu syndrom health sci pmid aaron la burk mm buchwald overlap condit patient chronic fatigu syndrom fibromyalgia temporomandibular disord arch intern med pmid nightingal foundat goldstein jay byron hyde clinic scientif basi myalgic encephalomyelitischron fatigu syndrom ogdensburg ni nightingal foundat role food intoler chronic fatigu syndrom isbn logan ac wong chronic fatigu syndrom oxid stress dietari modif altern medicin review journal clinic therapeut pmid mossmorri spenc lump split function somat syndrom infecti emot risk factor differenti onset chronic fatigu syndrom irrit bowel syndrom psychosomat medicin doi pmid behan po behan wm horrobin high dose essenti fatti acid postvir fatigu syndrom acta neurol scand pmid warren mckendrick peet role essenti fatti acid chronic fatigu syndrom casecontrol studi redcel membran essenti fatti acid efa placebocontrol treatment studi high dose efa acta neurol scand pmid carruth bm jain ak al myalgic encephomyel chronic fatigu syndrom clinic work case definit diagnost treatment protocol consensu document journal chronic fatigu syndrom essenti fatti acid pathophysiolog role clinic medicin york wileyliss isbn werbach april nutrit strategi treat chronic fatigu syndrom altern med rev pmid pliopli av pliopli amantadin lcarnitin treatment chronic fatigu syndrom neuropsychobiolog pmid reid chadler clear hotopf wess extract clinic evid chronic fatigu syndrom british medic journal cox campbel mj dowson red blood cell magnesium chronic fatigu syndrom lancet pmid afari eisenberg dm herrel al altern treatment chronic fatigu syndrom discord twin integr med pmid jone jf maloney em boneva rs jone ab reev wc complementari altern medic therapi util peopl chronic fatigu ill unit bmc complement altern med doi pmid malaguarnera gargant mp cristaldi al acetyl lcarnitin alc treatment elderli patient fatigu arch gerontol geriatr doi pmid vermeulen rc scholt hr exploratori open label random studi acetyl propionylcarnitin chronic fatigu syndrom psychosom med pmid chronic fatigu syndrom medic issu clinic descript etiolog pathophysiolog treatment manag societi histori histori altern controversi outbreak cultur refer notabl patient sophia mirza